Multiple myeloma or Monoclonal gammopathy of undetermined significance can also cause the condition.

Monoclonal gammopathy of undetermined significance.

Advances in understanding monoclonal gammopathy of undetermined significance as a precursor of multiple myeloma.

Monoclonal Gammopathy of Undetermined Significance: a consensus statement.

Monoclonal gammopathy of undetermined significance (MGUS) is not cancer but can become cancer.

Prevention of Progression in Monoclonal Gammopathy of Undetermined Significance.

A disease of gamma globulins is called a "gammopathy" (for example, in monoclonal gammopathy of undetermined significance.)

Abnormal bands (spikes) are seen in monoclonal gammopathy of undetermined significance and multiple myeloma, and are useful in the diagnosis of these conditions.

Standard Treatment Options for Monoclonal Gammopathy of Undetermined Significance (MGUS)

They include monoclonal gammopathy of undetermined significance (MGUS), isolated plasmacytoma of the bone, extramedullary plasmacytoma, and multiple myeloma.

Kyle RA, Rajkumar SV: Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression.

No generally accepted staging system exists for monoclonal gammopathy of undetermined significance (MGUS), isolated plasmacytoma of bone, or extramedullary plasmacytoma.

Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with monoclonal gammopathy of undetermined significance.

Detection of paraproteins in the urine or blood is most often associated with benign MGUS (monoclonal gammopathy of undetermined significance), where they remain "silent", and multiple myeloma.

Kyle RA, Therneau TM, Rajkumar SV, et al.: Prevalence of monoclonal gammopathy of undetermined significance.

Treatment of monoclonal gammopathy of undetermined significance (MGUS) is usually watchful waiting, which will include regular blood tests to check the level of M protein in the blood.

Waldenstrom's macroglobulinaemia (IgM), monoclonal gammopathy of undetermined significance (MGUS), amyloidosis, plasma cell leukemia and solitary plasmacytomas also produce an M-spike.

Rajkumar SV, Kyle RA, Therneau TM, et al.: Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance.

Landgren O, Kyle RA, Pfeiffer RM, et al.: Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.

People will sometimes develop a condition called MGUS (Monoclonal gammopathy of undetermined significance), where there is overproduction of one antibody but the condition is benign (does not threaten the patient's health).

In 2003, the International Myeloma Working Group agreed on diagnostic criteria for symptomatic myeloma, asymptomatic myeloma and MGUS (monoclonal gammopathy of undetermined significance), which was subsequently updated in 2009:

In monoclonal gammopathy of undetermined significance (MGUS), less than 10% of the bone marrow is made up of plasma cells, there is M protein in the blood, and there are no signs of cancer.

Initial research also suggests that measurement of free light chains may also be used, in conjunction with other markers, for assessment of the risk of progression from monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma.

Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering (asymptomatic) Multile Myeloma: IMWG consensus perspectives risk factors for progression and Guidelines for monitoring and management.

Billadeau D, Van Ness B, Kimlinger T, et al.: Clonal circulating cells are common in plasma cell proliferative disorders: a comparison of monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and active myeloma.